Poxel Announces Positive Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, A Novel, Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone Aug 30, 2022
Poxel Announces Extended Cash Runway with Debt Restructuring Agreement and Equity-linked Financing Facility Aug 8, 2022
Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2022 Aug 8, 2022
Poxel Announces the Publication of Two Preclinical Articles on X-Linked Adrenoleukodystrophy for PXL065 and PXL770 Jul 5, 2022
Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting Jun 22, 2022
Poxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041 Jun 9, 2022
Poxel Announces PXL065 and PXL770 Granted Orphan Drug Designation from the U.S. FDA for X-Linked Adrenoleukodystrophy May 17, 2022
